Comparison of Single-Dose Plasma and Blood Concentrations of Aripiprazole, Olanzapine, Quetiapine, Paliperidone and Risperidone After Capillary and Venous Blood Sample Collection

Trial Profile

Comparison of Single-Dose Plasma and Blood Concentrations of Aripiprazole, Olanzapine, Quetiapine, Paliperidone and Risperidone After Capillary and Venous Blood Sample Collection

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Aripiprazole (Primary) ; Olanzapine (Primary) ; Paliperidone (Primary) ; Quetiapine (Primary) ; Risperidone (Primary)
  • Indications Aggression; Agitation; Autistic disorder; Bipolar depression; Bipolar disorders; Borderline personality disorders; Dementia; Gilles de la Tourette's syndrome; Huntington's disease; Major depressive disorder; Manic episodes; Pervasive child development disorders; Schizoaffective disorder; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 01 Nov 2016 Results of this study, published in the Clinical Pharmacology in Drug Development.
    • 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Aug 2012 Planned End Date changed from 1 Jul 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top